{
  "docId": "019de075-c3df-7648-ab3f-403a3e018886",
  "docSlug": "132267474e075f06292187997a008f90",
  "documentTitle": "OmniAb | Investor Presentation Deck | 35 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 35,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "unfair_advantage",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The chart shows a clear upward trend in partner patent filings from 2014 to 2022.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-c3df-7648-ab3f-403a3e018886/25",
  "deckHref": "/decks/019de075-c3df-7648-ab3f-403a3e018886",
  "deckJsonHref": "/decks/019de075-c3df-7648-ab3f-403a3e018886.json",
  "deckAnchorHref": "/decks/019de075-c3df-7648-ab3f-403a3e018886#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.04,
        "y": 0.78
      },
      "kind": "callout",
      "text": "~80 patent filings by our partners claiming an OmniAb-derived antibody as primary invention, with expiries up to 2042",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "094bf670-625a-4ab6-97c9-67f306126cad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.35,
        "x": 0.04,
        "y": 0.28
      },
      "kind": "callout",
      "text": "Over 300 patents issued worldwide",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b679d1c-8f02-48a8-bd5f-4c4d48388df1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.22,
        "x": 0.75,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Antibody Patent Applications Filed by Partners",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a269ce03-574f-470a-9d6b-5060a879f427",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.65,
        "x": 0.04,
        "y": 0.4
      },
      "kind": "list",
      "text": "We maintain a broad intellectual property estate with multiple long duration patent families covering each major element of our technology platform. Licenses are structured so that royalties are linked to the patents for the antibodies discovered with OmniAb, thereby creating a lengthy coverage tail",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f75aacfc-869b-43b4-8cf4-1185c41f29ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.04,
        "y": 0.13
      },
      "kind": "title",
      "text": "PARTNERS FILING PATENTS ON OMNIAB-DERIVED ANTIBODIES CAN CREATE DIVERSE AND DURABLE ROYALTY STREAMS AND A LENGTHY IP TAIL",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "814bc103-9515-4561-b639-516845597036",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Intellectual Property Advantage",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74024a6f-d37f-4e93-b6f3-74702ddce5ed",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "047a31fa-d7a4-44e4-99dc-a9096f4c99b5",
      "evidence": "chart/bar-vertical: Antibody Patent Applications Filed by Partners",
      "confidence": 0.5
    },
    {
      "name": "Credibility Transfer",
      "slug": "credibility-transfer",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "3301abe2-9cb5-40eb-b0e9-b8d12ca8f5c5",
      "evidence": "list/bullet: ~80 patent filings by our partners claiming an OmniAb-derived antibody as primary invention",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 35,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1674fffb-efec-427e-b437-66fc0c0fd01e",
      "evidence": "The document presents the potential consequences of not investing in effective discovery technology.",
      "position": 0,
      "objective": "Highlight the importance of investing in OmniAb's technology to drive growth and success in the biotech industry.",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}